SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Lassila Riitta)
 

Search: WFRF:(Lassila Riitta) > Anti-Inhibitor Coag...

Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors

Leissinger, Cindy (author)
Gringeri, Alessandro (author)
Antmen, Bulent (author)
show more...
Berntorp, Erik (author)
Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups
Biasoli, Chiara (author)
Carpenter, Shannon (author)
Cortesi, Paolo (author)
Jo, Hyejin (author)
Kavakli, Kaan (author)
Lassila, Riitta (author)
Morfini, Massimo (author)
Negrier, Claude (author)
Rocino, Angiola (author)
Schramm, Wolfgang (author)
Serban, Margit (author)
Uscatescu, Marusia Valentina (author)
Windyga, Jerzy (author)
Zulfikar, Bulent (author)
Mantovani, Lorenzo (author)
show less...
 (creator_code:org_t)
2011
2011
English.
In: New England Journal of Medicine. - 0028-4793. ; 365:18, s. 1684-1692
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background Patients with severe hemophilia A and factor VIII inhibitors are at increased risk for serious bleeding complications and progression to end-stage joint disease. Effective strategies to prevent bleeding in such patients have not yet been established. Methods We enrolled patients with hemophilia A who were older than 2 years of age, had high-titer inhibitors, and used concentrates known as bypassing agents for bleeding in a prospective, randomized, crossover study comparing 6 months of anti-inhibitor coagulant complex (AICC), infused prophylactically at a target dose of 85 U per kilogram of body weight (+/- 15%) on 3 nonconsecutive days per week, with 6 months of on-demand therapy (AICC at a target dose of 85 U per kilogram [+/- 15%] used for bleeding episodes). The two treatment periods were separated by a 3-month washout period, during which patients received on-demand therapy for bleeding. The primary outcome was the number of bleeding episodes during each 6-month treatment period. Results Thirty-four patients underwent randomization; 26 patients completed both treatment periods and could be evaluated per protocol for the efficacy analysis. As compared with on-demand therapy, prophylaxis was associated with a 62% reduction in all bleeding episodes (P < 0.001), a 61% reduction in hemarthroses (P < 0.001), and a 72% reduction in target-joint bleeding (>= 3 hemarthroses in a single joint during a 6-month treatment period) (P < 0.001). Thirty-three randomly assigned patients received at least one infusion of the study drug and were evaluated for safety. One patient had an allergic reaction to the study drug. Conclusions AICC prophylaxis at the dosage evaluated significantly and safely decreased the frequency of joint and other bleeding events in patients with severe hemophilia A and factor VIII inhibitors. (Funded by Baxter BioScience; Pro-FEIBA ClinicalTrials.gov number, NCT00221195.)

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view